Researchers at the University of Pittsburgh Medical Center have developed a new ovarian cancer screening test that they claim has a specificity of 98 percent and a sensitivity of about 93 percent, giving it a higher diagnostic power than any other published ovarian cancer assay to date.

UPMC researchers led by Anna Lokshin, an assistant professor of medicine and pathology, used a biomarker panel comprising 20 proteins to test 150 ovarian cancer patients and 150 controls.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.